Estonia is a developed country with an advanced, high-income economy that has been among the fastest-growing in the EU. In the Human Development Index, Estonia ranks very high and does well in measures of economic freedom, civil liberties, education and press freedom.
All the citizens are provided with universal healthcare, free education and also the longest paid maternity leave in the OECD.
GDP per capita
A member of the European Union since 2004, Estonia is among the wealthiest nations in the Baltic region. Likewise, the country has a modern health system that can reasonably support its population of 1.3 million. Estonia’s healthcare system has been revolutionized by innovative e-solutions. Patients and doctors, not to mention hospitals and the government, benefit from the convenient access and savings that e-services have delivered.
Each person in Estonia that has visited a doctor has an online e-Health record that can be tracked. Identified by the electronic ID-card, the health information is kept completely secure and at the same time accessible to authorised individuals. KSI Blockchain technology is being used for the system to ensure data integrity and mitigate internal threats to the data.
Estonia have signed the Joint Baltic Drug Procurement Agreement. This agreement may increase the volume of ordered medicines, thus attracting interest from more pharmaceutical companies to participate in tenders and putting manufacturers under pressure to offer discounts on pharmaceutical prices.
Obesity is a big issue in Estonia. There’s still controversy over whether obesity is actually a “disease,” but reports and data on public health in Estonia have outlined it as a clear issue. Obesity can greatly increase the risk of a myriad of health issues, including diabetes, heart disease and stroke. Heart disease and stroke accounted for nearly half of all deaths in Estonia in 2012 (48 percent), so many physicians believe the issue should be taken seriously as one of the top diseases in Estonia.
Estonia faces unique but surmountable public health challenges. The government likely has the means to solve such issues, and the nation, therefore, serves as a good example of how funding is not the only weapon fights like these; there must be political attention, commitment and patience.
Henrik Alfredsson & Clas Lindbergson
Challenge us with your case and we will show you the possibilities for your product.
Sales and Marketing
Entering the European market is not easy. 44 countries with different healthcare systems. What is your strategy? Apart from the Big-5, what do you do with the other 28 countries? We offer a solution for 28 countries. Sales and marketing is our core business.Learn more
We manage, through our logistic partners with their regional warehouses, the distribution to our region (28 countries). They have the capability to handle the most demanding of specialized product order management, storage, handling and distribution requirements.Learn more
Early Market Research
You know that market research is critical. It provides customer insights, competitive intelligence, behavioural tendencies, and product positioning. And market research increasingly is becoming an important component for linking R&D and marketing teams.Learn more
Achieving reimbursement and getting the right price are the 2 most important drivers for a successful launch of an innovative pharmaceuticals in our part of Europe. Health Authorities in any European country decide individually based on their local regulations, policies, framework, social values and available health care budget.Learn more
Unlike other regions, in the EU a number of options is available to obtain a marketing authorisation. Centralised at the European Medicines Agency in Amsterdam or decentralised with the individual competent authorities of the member states, each marketing authorisation application procedure has its pros and cons. In the case of Switzerland, it has its own regulatory authority, Swissmedic, and processes.Learn more
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.Learn more